BNR (Burning Rock Biotech) Other Current Receivables: $1.85 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNR Burning Rock Biotech Ltd BNR
59 GF Score
Price $9.45
GF Value $7.47
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Other Current Receivables?

Burning Rock Biotech BNR -6.16% 59 Other Current Receivables is $1.85 Mil as of Mar. 2026. GuruFocus rates BNR with a GF Score™ of 59/100 and a GF Value™ of $7.47 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Burning Rock Biotech's Other Current Receivables for the quarter that ended in Mar. 2026 was $1.85 Mil.

Burning Rock Biotech's quarterly Other Current Receivables increased from Sep. 2025 ($1.83 Mil) to Dec. 2025 ($3.29 Mil) but then stayed the same from Dec. 2025 ($3.29 Mil) to Mar. 2026 ($1.85 Mil).

Burning Rock Biotech's annual Other Current Receivables declined from Dec. 2023 ($5.74 Mil) to Dec. 2024 ($2.94 Mil) but then increased from Dec. 2024 ($2.94 Mil) to Dec. 2025 ($3.29 Mil).

Burning Rock Biotech Other Current Receivables Related Terms

Burning Rock Biotech Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Burning Rock Biotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burning Rock Biotech Other Current Receivables Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 10.32 8.65 5.74 2.94 3.29

Burning Rock Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 2.06 1.83 3.29 1.85
BNR
59GF Score
Burning Rock Biotech Ltd BNR
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Burning Rock Biotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $1.85 Mil mean?
Burning Rock Biotech (BNR) has a Other Current Receivables of $1.85 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Other Current Receivables too high?
Burning Rock Biotech's current Other Current Receivables is $1.85 Mil. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Other Current Receivables compare to XGN and IDXG?
Burning Rock Biotech's Other Current Receivables of $1.85 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Other Current Receivables is $1.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.47, compared to a current price of $9.45 — trading 26.5% above its estimated fair value. The current Other Current Receivables is $1.85 Mil. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Other Current Receivables is $1.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (BNR) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of $9.45 is trading 26.5% above its estimated GF Value™ of $7.47. GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.

Key valuation signals for BNR:

  • Other Current Receivables: $1.85 Mil
  • GF Value™: $7.47 vs. price of $9.45 (26.5% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges 6BU0:Germany
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score

Get the complete analysis for BNR

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.45
Price
$7.47
GF Value